The experience of inhibitirs of tumor necrosis factor-α administration in patients with ankylosing spondilitis and psoriatic arthritis
Summary. Summary. The article studies the efficiency and tolerability of the infliximab (INF) and adalimumab (ADA) biological therapy (BT) in 14 patients with ankylosing spondylitis (AS) and in 4 patients with psoriatic arthritis (PsA). After 3 months of the BT the AS activity considerably decreased and the functional state of the patients improved: the BASDAI and the BASFI dropped by 65%, the C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) dropped by 76.7% and 75.2% correspondingly. The changes remained stable during 9 months of the treatment, except for a slight ESR increase in the 9th month in comparison with the 3rd one. At that, the average ESR was within referential meaning. After 3 months of the INF treatment in the PsA patients with peripheral joints lesion there was a 90.1% decrease in the number of tender joints and there were no swollen joints. After 6 months there were neither tender nor swollen joints. After 3 and 6 months the psoriasis area and severity index (PASI) dropped by 92.8% and 80.8% correspondingly in comparison with the outgoing data. After 9 months of the treatment in the group of AS and PsA patients with a conditionally early BT initiation (less than 78 months from the disease onset) the CRP level decrease was considerably higher in comparison with a late BT initiation and there was also noticed a tendency to a more pronounced clinical effect. The therapy tolerance was high in 77.8% of cases, satisfactory in 22.2% of cases and there were no patients who refused completion of the therapy because of adverse events.
No Comments » Add your